Dr. Cacoub has received consulting fees or honoraria (less than $10,000 each) from Sanofi-Aventis, Schering-Plough, Servier, and Roche.
Antiviral therapy for hepatitis C virus–associated mixed cryoglobulinemia vasculitis: A long-term followup study
Article first published online: 30 OCT 2006
Copyright © 2006 by the American College of Rheumatology
Arthritis & Rheumatism
Volume 54, Issue 11, pages 3696–3706, November 2006
How to Cite
Saadoun, D., Resche-Rigon, M., Thibault, V., Piette, J.-C. and Cacoub, P. (2006), Antiviral therapy for hepatitis C virus–associated mixed cryoglobulinemia vasculitis: A long-term followup study. Arthritis & Rheumatism, 54: 3696–3706. doi: 10.1002/art.22168
- Issue published online: 30 OCT 2006
- Article first published online: 30 OCT 2006
- Manuscript Accepted: 17 JUL 2006
- Manuscript Received: 20 MAR 2006
To evaluate the long-term efficacy of anti–hepatitis C virus (HCV) therapy in patients with HCV-associated mixed cryoglobulinemia (HCV-MC) vasculitis and to assess the factors associated with clinical remission of MC.
This was a single-center study of 72 consecutive patients who received treatment with IFN alfa-2b (3 million IU 3 times a week; n = 32 patients) or PEGylated IFN alfa-2b (PEG–IFN alfa-2b) (1.5 μg/kg/week; n = 40 patients), both in combination with oral ribavirin (600–1,200 mg/day), for at least 6 months. Logistic regression was used to assess factors associated with clinical remission of MC.
The mean ± SD duration of followup after discontinuation of antiviral therapy was 39.7 ± 24.4 months. Eight deaths (11.1% of patients) occurred during the study, primarily as a result of cardiovascular disease, liver disease, or infection. A complete clinical response of the MC occurred in 45 patients (62.5%), a sustained virologic response occurred in 58.3%, and cryoglobulins cleared in 45.8%. Compared with patients treated with IFN alfa-2b plus ribavirin, those receiving PEG–IFN alfa-2b plus ribavirin had a higher sustained clinical (67.5% versus 56.3%), virologic (62.5% versus 53.1%), and immunologic (57.5% versus 31.3%) response, regardless of HCV genotype and viral load. In multivariate analyses, an early virologic response (odds ratio 3.53 [95% confidence interval 1.18–10.59]) was independently associated with a complete clinical response of MC. A glomerular filtration rate ≤70 ml/minute (odds ratio 0.18 [95% confidence interval 0.05–0.67]) was negatively associated with a complete clinical response of MC.
PEG–IFN alfa-2b plus ribavirin should be considered as induction therapy for HCV-MC vasculitis. An early virologic response and the absence of renal insufficiency are the key factors in the clinical response.